Hepatocyte MLKL accumulation in aging livers drives mitochondrial dysfunction and cellular senescence independent of necroptosis, amplifying inflammatory signaling across liver tissue through paracrine mechanisms. This identifies MLKL as a direct molecular driver of liver aging with potential therapeutic relevance to metabolic liver disease progression.
Key Points
- MLKL promotes senescence via mitochondrial dysfunction, not necroptotic cell death
- Damaged mitochondria trigger pro-inflammatory extracellular vesicle release
- Senescence spreads to immune and structural cells through paracrine signaling
Longevity Analysis
This research clarifies a specific mechanism by which aging accelerates liver pathology: mitochondrial stress in hepatocytes generates oxidative signals that senescence neighboring cells, creating a self-amplifying inflammatory loop. Understanding this paracrine amplification pathway reveals why isolated interventions often fail—senescence burden accumulates across multiple cell populations simultaneously. Targeting MLKL-driven mitochondrial dysfunction addresses a root cause rather than downstream inflammation, suggesting a more durable approach to slowing metabolic liver disease in aging.
Original published by Wiley Aging Cell, by Sabira Mohammed, Chao Jiang, Travis Pennington, Shylesh Bhaskaran, Phoebe Ohene‐Marfo, Kara F. Kneuper, Constantin Georgescu, Kamille Pitts, Albert Tran, Zongkai Peng, Amit Singh, Zhibo Yang, Tiangang Li, Bethany Hannafon, Courtney Houchen, Jonathan D. Wren, Andriy Yabluchanskiy, Veronica Galvan, Nagib Ahsan, Michael Kinter, Tommy L. Lewis Jr, Sathyaseelan S. Deepa .